394 related articles for article (PubMed ID: 23752091)
1. Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.
Li X; Semenova S; D'Souza MS; Stoker AK; Markou A
Neuropharmacology; 2014 Jan; 76 Pt B(0 0):554-65. PubMed ID: 23752091
[TBL] [Abstract][Full Text] [Related]
2. The "stop" and "go" of nicotine dependence: role of GABA and glutamate.
D'Souza MS; Markou A
Cold Spring Harb Perspect Med; 2013 Jun; 3(6):. PubMed ID: 23732855
[TBL] [Abstract][Full Text] [Related]
3. Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.
Liechti ME; Markou A
CNS Drugs; 2008; 22(9):705-24. PubMed ID: 18698872
[TBL] [Abstract][Full Text] [Related]
4. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments.
D'Souza MS; Markou A
Addict Sci Clin Pract; 2011 Jul; 6(1):4-16. PubMed ID: 22003417
[TBL] [Abstract][Full Text] [Related]
5. Neuroscience of nicotine for addiction medicine: novel targets for smoking cessation medications.
D'Souza MS
Prog Brain Res; 2016; 223():191-214. PubMed ID: 26806777
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor 5 as a potential target for smoking cessation.
Chiamulera C; Marzo CM; Balfour DJK
Psychopharmacology (Berl); 2017 May; 234(9-10):1357-1370. PubMed ID: 27847973
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.
Cross AJ; Anthenelli R; Li X
Biol Psychiatry; 2018 Jun; 83(11):947-954. PubMed ID: 29301614
[TBL] [Abstract][Full Text] [Related]
8. Review. Neurobiology of nicotine dependence.
Markou A
Philos Trans R Soc Lond B Biol Sci; 2008 Oct; 363(1507):3159-68. PubMed ID: 18640919
[TBL] [Abstract][Full Text] [Related]
9. Endogenous opioid system: a promising target for future smoking cessation medications.
Norman H; D'Souza MS
Psychopharmacology (Berl); 2017 May; 234(9-10):1371-1394. PubMed ID: 28285326
[TBL] [Abstract][Full Text] [Related]
10. More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.
Moerke MJ; McMahon LR; Wilkerson JL
Pharmacol Rev; 2020 Apr; 72(2):527-557. PubMed ID: 32205338
[TBL] [Abstract][Full Text] [Related]
11. New mechanisms and perspectives in nicotine withdrawal.
Jackson KJ; Muldoon PP; De Biasi M; Damaj MI
Neuropharmacology; 2015 Sep; 96(Pt B):223-34. PubMed ID: 25433149
[TBL] [Abstract][Full Text] [Related]
12. Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.
Fowler CD; Kenny PJ
Neuropharmacology; 2014 Jan; 76 Pt B(0 0):533-44. PubMed ID: 24055497
[TBL] [Abstract][Full Text] [Related]
13. Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.
Smith LC; George O
Neuropharmacology; 2020 Nov; 178():108225. PubMed ID: 32758566
[TBL] [Abstract][Full Text] [Related]
14. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.
Berrendero F; Robledo P; Trigo JM; Martín-García E; Maldonado R
Neurosci Biobehav Rev; 2010 Nov; 35(2):220-31. PubMed ID: 20170672
[TBL] [Abstract][Full Text] [Related]
15. Double target concept for smoking cessation.
Wu J
Acta Pharmacol Sin; 2010 Sep; 31(9):1015-8. PubMed ID: 20711220
[TBL] [Abstract][Full Text] [Related]
16. The effect of N-acetylcysteine on brain glutamate and gamma-aminobutyric acid concentrations and on smoking cessation: A randomized, double-blind, placebo-controlled trial.
Schulte M; Goudriaan AE; Kaag AM; Kooi DP; van den Brink W; Wiers RW; Schmaal L
J Psychopharmacol; 2017 Oct; 31(10):1377-1379. PubMed ID: 28922968
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of lateral hypothalamic glutamate and acetylcholine efflux by nicotine: implications for mechanisms of nicotine-induced activation of orexin neurons.
Pasumarthi RK; Fadel J
J Neurochem; 2010 May; 113(4):1023-35. PubMed ID: 20236223
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic receptor-based therapeutics and candidates for smoking cessation.
Dwoskin LP; Smith AM; Wooters TE; Zhang Z; Crooks PA; Bardo MT
Biochem Pharmacol; 2009 Oct; 78(7):732-43. PubMed ID: 19523455
[TBL] [Abstract][Full Text] [Related]
19. Neonatal nicotine exposure increases excitatory synaptic transmission and attenuates nicotine-stimulated GABA release in the adult rat hippocampus.
Damborsky JC; Griffith WH; Winzer-Serhan UH
Neuropharmacology; 2015 Jan; 88():187-98. PubMed ID: 24950455
[TBL] [Abstract][Full Text] [Related]
20. Nicotinic receptor antagonists as treatments for nicotine abuse.
Crooks PA; Bardo MT; Dwoskin LP
Adv Pharmacol; 2014; 69():513-51. PubMed ID: 24484986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
